The MFDS approved the official approval based on the results report of phase 3 clinical trials of Celltrion's COVID-19 antibody treatment Rekirona, which completed phase 3 global submitted by the company. It has expanded the subject of administration. However, mild patients were not included. The MFDS announced on the 17th that it had carefully reviewed the results of a global phase 3 clinical trial of Rekirona (Regdanvimab), a domestic COVID-19 antibody treatment submitted by Celltrion on the 10th of last month, and approved the change to delete the permit conditions and expand the range of patients who can be administered.

As the efficacy and effect of Rekirona was allowed to be changed to "treatment